logo
Share SHARE
FONT-SIZE Plus   Neg

Bristol-Myers, Pfizer Says Eliquis Late-Stage Trial Meets Main Goal

Bristol-Myers Squibb Co. (BMY: Quote) and Pfizer Inc. (PFE: Quote) Sunday said its anti-clotting drug Eliquis proved to be as effective as standard therapy and caused significantly less bleeding complications in in treating patients with acute venous thromboembolism.

Eliquis met the main endpoint of the trial by demonstrating that it is not inferior to the current standard of care, ainitial parenteral enoxaparin treatment overlapped with warfarin therapy, in the reduction of recurrence of acute venous thromboembolism, or VTE, and related deaths.

Eliquis also met the primary safety endpoint of superiority for major bleeding, with a 69 percent relative risk reduction compared to current standard of care.

Eliquis, or apixaban, is an anticoagulant that was jointly developed by Bristol-Myers Squibb and Pfizer. Eliquis is approved for prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery in the EU and other countries, but the drug has not been is not approved for this indication in the U.S.

"The study results showed that apixaban, as a single-agent, has comparable efficacy with significantly fewer major bleeding events with respect to the standard of care," said Dr. Giancarlo Agnelli, the lead investigator of the study. "Together these studies represent exciting data in the field of VTE treatment and indicate that apixaban may offer an important potential alternative in both acute and extended anticoagulation therapy for VTE patients."

Venous thromboembolism encompasses two serious conditions: deep vein thrombosis (DVT), a blood clot in a vein, usually in the leg; and pulmonary embolism (PE), a blood clot blocking one or more vessels in the lungs. Around 900,000 patients in the U.S. and about 1 million patients in the EU are diagnosed every year with VTE.

The study, dubbed AMPLIFY, (Apixaban for the initial Management of PuLmonary embolIsm and deep vein thrombosis as First-line therapY), included 5,395 patients. The study tested 10 mg of Eliquis twice daily for seven days followed by 5 mg twice daily thereafter compared to current standard of care.

PFE closed Friday at $28.01, down $0.17 or 0.60%, while BMY closed at $44.69, down $1.61 or 3.48%, both on the NYSE.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Software giant Microsoft Corp. said Monday after the markets closed that its second quarter profit fell 11% from last year, hurt mainly by integration and restructuring costs as well as higher income tax expenses even as revenue increased 8% due to strong sales of its gadgets and cloud-based products. English-made Cadbury chocolates will no longer be available in the United States, the result of a settlement between Hershey and a New Jersey-based import company. Beloved treats such as the Cadbury Creme Egg will only be sold in the U.S. using American chocolate, angering those who say the creamier... Gas prices are set to climb again after a long time due to rising wholesale prices. According to Lundberg Survey, while the national average price of gas fell 13 cents in the past two weeks to $2.07 a gallon, it could soon rise due to increased costs of crude oil in the past 10 days.
comments powered by Disqus
Follow RTT